GOLO will not be liable for any errors, losses, injuries, or damages from the display or use of this information
Haykal D, Hersant B, Cartier H, Meningaud JP
However, when combined with insulin or sulphonylureas, the risk increases, and dose adjustments of these concurrent medications may be necessary
The compound is frequently referred to as a triple-hormone-receptor agonist retatrutide because it simultaneously targets: GLP-1 receptor pathways Glucagon receptor pathways Glucose-dependent insulinotropic polypeptide receptor pathways This triple agonist mechanism differentiates retatrutide from earlier GLP-1 receptor agonist compounds and other research peptides currently studied for obesity and metabolic dysfunction
Its regulatory status depends on the country and the latest approvals
Injectable GLP-1 RAs like liraglutide, semaglutide, and dulaglutide have been shown to significantly lower HbA1c and body weight in patients with T2DM